


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR


 $R_1, R_2, R_3 = G_1 = O, N, AK \checkmark$

G1 O, N, Ak

G2 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s L1 full

FULL SEARCH INITIATED 09:38:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2549 TO ITERATE

 100.0% PROCESSED 2549 ITERATIONS
 SEARCH TIME: 00.00.01

181 ANSWERS

L2 181 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

172.55

TOTAL

SESSION

172.76

FILE 'CAPLUS' ENTERED AT 09:38:36 ON 28 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 22 L2

=> d ibib abs hitstr 1-22

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2007:14089 CAPLUS

DOCUMENT NUMBER:

146:120541

TITLE:

INVENTOR(S): Aoki, Masahiro; Nagahashi, Yoshie; Kato, Hideyuki;

PATENT ASSIGNEE(S):

SOURCE:

PCT Int. Appl., 81pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000994	A1	20070104	WO 2006-JP312798	20060627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CH, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

JP 2005-188765

A 20050628


OTHER SOURCE(S):

MARPAT 146:120541

GI

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



AB It is intended to provide a simple and inexpensive method of producing a compound which has a high activity of inhibiting replication of hepatitis C virus (HCV) and is useful for preventing and treating a liver disease caused by HCV infection. It is a method of biol. producing a compound

(I: A = H, linear or branched C1-8 alkyl group) or a pharmaceutical acceptable salt with II-producing Fusarium incarnatum from amino acid derivs. The morphol. and physiol. characteristics of the F. incarnatum were also given.

IT 827034-92-4P 827035-10-9P 827035-62-1P

827035-65-4P 876404-54-5P

RI: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)

(Manufacture of anti-HCV drugs with Fusarium from amino acid derivs.)


RN 827034-92-4 CAPLUS

CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[(4-(2-butyloxy)phenyl)-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-10-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-pyridinyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 827035-62-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B


OMe

RN 827035-65-4 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(2'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 876404-54-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-methyl-2-butenyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT:

19

THIS

THERE ARE 19 CITED REFERENCES AVAILABLE FOR

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:845652 CAPLUS
 DOCUMENT NUMBER: 145:272019
 TITLE: Process for producing compound with anti-HCV potency and intermediate for use therein
 INVENTOR(S): Kato, Tatsuya; Kimura, Nobuaki; Mizutani, Akemi; Makino, Toshihiko; Kawasaki, Kenichi; Fukuda, Hiroshi;
 Komiya, Susumu; Tsukuda, Takuo
 PATENT ASSIGNEE(S): Chugai Seliyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 112pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088071	A1	20060824	WO 2006-JP302687	20060216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, VU, ZA, ZM, ZW

RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: JP 2005-41153 A 20050217

OTHER SOURCE(S): MARPAT 145:272019
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for the preparation of the compds. of formula I [Y = (un)substituted 2-oxazolidinonyl or 2-oxazolidinethionyl; Q = protected carbonyl; m = 0-10; n = 0-10; R' = H, (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl or heterocyclyl; P = OH protecting group] comprising reacting a compound of formula II [Y, Q, R', m and n are defined as above] with a compound of formula III [P = OH protecting group; P' = protecting group of carboxyl] is disclosed. For example, IV was provided in a multi-step synthesis starting from monomethyl azelaic acid. I have a desirable optical activity and can be synthesized selectively in high yield through a reduced number of steps, they may be useful as inhibitors of HCV replication (no data, no claim).
 IT 906651-47-6P 906651-49-8P 906651-55-6P

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2
 CRN 101-83-7
 CMF C12 H23 N



RN 906651-55-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-1-[[4-(2-butyloxy)phenyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-58-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-

5-[[[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 906651-58-9P 906651-59-0P 906651-63-6P
 906651-64-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of L-tyrosine derivs. with anti-HCV potency and their intermediates)
 RN 906651-47-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-1-[[4-(2-butyloxy)phenyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-49-8 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-1-[[4-(2-butyloxy)phenyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 906651-47-6
 CMF C43 H65 N O10

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-59-0 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-

5-[[[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-2-oxoethyl]amino]-5-C-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)


CM 1
 CRN 906651-58-9
 CMF C46 H67 N O10

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 101-83-7
 CMF C12 H23 N



RN 906651-63-6 CAPLUS
 CN D-erythro-Pentonic acid,
 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-
 5-[[[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-
 2-oxoethyl]amino]-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-
 oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 906651-64-7 CAPLUS
 CN D-erythro-Pentonic acid,
 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-
 5-[[[(1S)-2-(1,1-dimethylethoxy)-1-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-
 2-oxoethyl]amino]-4-[(1E)-8-(2-heptyl-1,3-dioxolan-2-yl)-1-octenyl]-5-C-
 oxo-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX
 NAME)

CM 1

CRN 906651-63-6
 CMF C48 H71 N O11


Absolute stereochemistry.

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-62-1 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-methoxy[1,1'-
 biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

PAGE 1-B


REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.



CM 2


CRN 101-83-7
 CMF C12 H23 N



IT 827034-92-4P 827035-62-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of L-tyrosine derivs. with anti-HCV potency and their
 intermediates)
 RN 827034-92-4 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-(2-butyloxy)phenyl]-1-
 carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:646516 CAPLUS
 DOCUMENT NUMBER: 145:271525
 TITLE: A Simple, Short, and Flexible Synthesis of
 Viridifungin Derivatives
 AUTHOR(S): Goldup, Stephen M.; Pilkington, Christopher J.;
 White, Andrew J. P.; Burton, Andrew; Barrett, Anthony G. M.
 CORPORATE SOURCE: Department of Chemistry, Imperial College London,
 London, SW7 2AZ, UK
 SOURCE: Journal of Organic Chemistry (2006), 71(16),
 6185-6191
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:271525
 GI



AB Described herein is a simple, flexible, and efficient synthesis of the
 skeleton of the viridifungins, a family of microbial secondary
 metabolites. The synthesis utilizes asym. aldol reaction of chiral
 oxazolidinone I with Et glyoxalate, diastereoselective alkylation of
 chiral 1,3-dioxolan-2-one II with tert-Bu bromoacetate, and a
 geometrically selective alkene cross-metathesis reaction as the key C-C
 bond-forming steps.
 IT 907189-17-7
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of viridifungins with vinyl malate and vinyl citrate
 as key intermediates via stereoselective aldol addition, enolate
 alkylation and cross metathesis)
 RN 907189-17-7 CAPLUS
 CN L-Tyrosine,
 N-[2,4-dideoxy-5-O-(1,1-dimethylethyl)-3-C-(methoxycarbonyl)-5-
 C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-erythro-pentonoyl]-O-(1,1-
 dimethylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:268345 CAPLUS
DOCUMENT NUMBER: 144:310621
TITLE: Anti-HCV compounds and their medical compositions
INVENTOR(S): Aoki, Masahiro; Kato, Hideyuki; Ito, Tatsuya; Itezo, Keiko; Sudo, Masayuki
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006077004	A	20060323	JP 2005-231587	20050810
PRIORITY APPL. INFO.:			JP 2004-234699	A 20040811

OTHER SOURCE(S): MARPAT 144:310621
GI




AB Claimed are title compds. I [R1-R3 = H, OH, (un)substituted NH2, C1-4 linear or branched alkyl(oxy), C2-4 linear or branched alkenyl(oxy), C2-4 alkynyl(oxy); A = H, (un)substituted C5 linear or branched alkenyl; B = H, halo, (un)substituted NH2, (un)substituted NOH, etc.; C = (un)substituted linear or branched C7 alkyl, alkenyl, alkynyl; Q = single or double bond; when A = H or alkenyl, then C = (OH-substituted) linear or branched C7 alkenyl or 2-hydroxy-n-heptyl], their prodrugs, or pharmaceut. acceptable salts. Thus, Fusarium sp. F1476 was shake-cultured in a medium containing glucose, glycerin, potato starch, etc., to manufacture II, which inhibited replicon with IC50 value of 956 nM and cytotoxicity CC50 value of 7400 nM.
IT 879872-40-9P 879872-41-0P 879872-42-1P
879873-72-0P 879873-73-1P 879873-74-2P
879873-75-3P
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); PAC

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN L-Tyrosine, N-[(1S,3E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3-octadecenyl]-O-[(2E)-4-hydroxy-3-methyl-2-butenyl]- (9CI) (CA INDEX NAME)


MANUF. OF TYROSINES AS ANTI-HCV AGENTS WITH FUSARIUM SP.)
RN 879872-40-9 CAPLUS
CN L-Tyrosine, N-[(1S,3E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3-octadecenyl]-O-[(2E)-4-hydroxy-3-methyl-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879872-41-0 CAPLUS
CN L-Tyrosine, N-[(1S,3E,12E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3,12-octadecadienyl]-O-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN L-Tyrosine, N-[(1S,3E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,11-dioxo-3-octadecenyl]-O-[(2E)-4-hydroxy-3-methyl-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879873-72-0 CAPLUS
CN L-Tyrosine, N-[(2S,3E,13E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-1,12-dihydroxy-1-oxo-3,13-octadecadienyl]-O-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.



RN 879873-73-1 CAPLUS
CN L-Tyrosine, N-[(3-C-carboxy-2,4-dideoxy-2-[(1E)-11-hydroxy-9-oxo-1-hexadecenyl]-5-C-oxo-L-erythro-pentonyl]-O-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.
Currently available stereo shown.

Me

RN 879872-42-1 CAPLUS

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Me

RN 879873-74-2 CAPLUS
 CN L-Tyrosine, N-[(2S,3E,13E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-11-hydroxy-1-oxo-3,13-octadecadienyl]-O-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.
 Currently available stereo shown.



RN 879873-75-3 CAPLUS
 CN L-Tyrosine, N-[(2S,3E,12E)-2-[(1S)-1,2-dicarboxy-1-hydroxyethyl]-11-hydroxy-1-oxo-3,12-octadecadienyl]-O-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:152763 CAPLUS
 DOCUMENT NUMBER: 144:226248
 TITLE: Drug for treating or preventing HCV infection
 INVENTOR(S): Sudo, Masayuki; Sakamoto, Hiroshi
 PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016657	A1	20060216	WO 2005-JP14767	20050811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		JP 2004-234900 A 20040811		

OTHER SOURCE(S): MARPAT 144:226248
 AB By discussing the HCV replicon inhibitory activities of compds. originating in microorganisms such as one belonging to the genus Aureobasidium, myricetin, fumonisins B1 and a ceramide transportation inhibitor HPA-12, it is observed that these compds. have effects of inhibiting the replication of HCV replicon RNA or inhibiting the expression of the HCV protein. By performing a knockdown experiment on serine palmitoyl transferase with the use of siRNA, it is found out that the HCV replicon activity and the expression of the HCV protein are significantly inhibited in cells wherein the expression of LCBI is regulated, suggesting that sphingo lipid biosynthesis might participate in HCV infection. Based on these facts, it is clarified that HCV infection can be treated or prevented by inhibiting an enzyme activity occurring in the process of sphingo lipid biosynthesis by the addition of a compound or the knockdown of a gene.

IT 147023-34-5 147023-36-7 744208-70-6
 745782-40-5 827034-86-6 827034-88-8
 827034-90-2 827034-92-4 827034-94-6
 827034-96-8 827034-98-0 827035-00-7
 827035-02-9 827035-04-1 827035-06-3
 827035-08-5 827035-10-9 827035-12-1
 827035-14-3 827035-16-5 827035-18-7
 827035-20-1 827035-21-2 827035-23-4
 827035-25-6 827035-27-8 827035-28-9
 827035-29-0 827035-30-3 827035-31-4
 827035-32-5 827035-33-6 827035-34-7

L3 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Double bond geometry as shown.
 Currently available stereo shown.

PAGE 1-A




PAGE 1-B

Me

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


827035-35-8 827035-36-9 827035-38-1
 827035-40-5 827035-41-6 827035-42-7
 827035-43-8 827035-45-0 827035-46-1
 827035-50-7 827035-51-9 827035-52-0
 827035-53-1 827035-54-2 827035-55-3
 827035-56-4 827035-57-5 827035-58-6
 827035-59-7 827035-60-8 827035-61-9
 827035-62-0 827035-63-1 827035-64-2
 827035-65-3 827035-66-4 827035-67-5
 827035-68-6 827035-69-7 827035-70-8
 827035-71-9 827035-72-0 827035-73-1
 827035-74-2 827035-75-3 827035-76-4
 827035-77-5 827035-78-6 827035-79-7
 827035-80-8 827035-81-9 827035-82-0
 827035-83-1 827035-84-2 827035-85-3
 827035-86-4 827035-87-5 827035-88-6
 827035-89-7 827035-90-8 827035-91-9
 827035-92-0 827035-93-1 827035-94-2
 827035-95-3 827035-96-4 827035-97-5
 827035-98-6 827035-99-7 827036-00-8
 827036-01-9 827036-02-0 827036-03-1
 827036-04-2 827036-05-3 827036-06-4
 827036-07-5 827036-08-6 827036-09-7
 827036-10-8 827036-11-9 827036-12-0
 827036-13-1 827036-14-2 827036-15-3
 827036-16-4 827036-17-5 827036-18-6
 827036-19-7 827036-20-8 827036-21-9
 827036-22-0 827036-23-1 827036-24-2
 827036-25-3 827036-26-4 827036-27-5
 827036-28-6 827036-29-7 827036-30-8
 827036-31-9 827036-32-0 827036-33-1
 827036-34-2 827036-35-3 827036-36-4
 827036-37-5 827036-38-6 827036-39-7
 827036-40-8 827036-41-9 827036-42-0
 827036-43-1 827036-44-2 827036-45-3
 827036-46-4 827036-47-5 827036-48-6
 827036-49-7 827036-50-8 827036-51-9
 827036-52-0 827036-53-1 827036-54-2
 827036-55-3 827036-56-4 827036-57-5
 827036-58-6 827036-59-7 827036-60-8
 827036-61-9 827036-62-0 827036-63-1
 827036-64-2 827036-65-3 827036-66-4
 827036-67-5 827036-68-6 827036-69-7
 827036-70-8 827036-71-9 827036-72-0
 827036-73-1 827036-74-2 827036-75-3
 827036-76-4 827036-77-5 827036-78-6
 827036-79-7 827036-80-8 827036-81-9
 827036-82-0 827036-83-1 827036-84-2
 827036-85-3 827036-86-4 827036-87-5
 827036-88-6 827036-89-7 827036-90-8
 827036-91-9 827036-92-0 827036-93-1
 827036-94-2 827036-95-3 827036-96-4
 827036-97-5 827036-98-6 827036-99-7
 827037-00-8 827037-01-9 827037-02-0
 827037-03-1 827037-04-2 827037-05-3
 827037-06-4 827037-07-5 827037-08-6
 827037-09-7 827037-10-8 827037-11-9
 827037-12-0 827037-13-1 827037-14-2
 827037-15-3 827037-16-4 827037-17-5
 827037-18-6 827037-19-7 827037-20-8
 827037-21-9 827037-22-0 827037-23-1
 827037-24-2 827037-25-3 827037-26-4
 827037-27-5 827037-28-6 827037-29-7
 827037-30-8 827037-31-9 827037-32-0
 827037-33-1 827037-34-2 827037-35-3
 827037-36-4 827037-37-5 827037-38-6
 827037-39-7 827037-40-8 827037-41-9
 827037-42-0 827037-43-1 827037-44-2
 827037-45-3 827037-46-4 827037-47-5
 827037-48-6 827037-49-7 827037-50-8
 827037-51-9 827037-52-0 827037-53-1
 827037-54-2 827037-55-3 827037-56-4
 827037-57-5 827037-58-6 827037-59-7
 827037-60-8 827037-61-9 827037-62-0
 827037-63-1 827037-64-2 827037-65-3
 827037-66-4 827037-67-5 827037-68-6
 827037-69-7 827037-70-8 827037-71-9
 827037-72-0 827037-73-1 827037-74-2
 827037-75-3 827037-76-4 827037-77-5
 827037-78-6 827037-79-7 827037-80-8
 827037-81-9 827037-82-0 827037-83-1
 827037-84-2 827037-85-3 827037-86-4
 827037-87-5 827037-88-6 827037-89-7
 827037-90-8 827037-91-9 827037-92-0
 827037-93-1 827037-94-2 827037-95-3
 827037-96-4 827037-97-5 827037-98-6
 827037-99-7 827038-00-8 827038-01-9
 827038-02-0 827038-03-1 827038-04-2
 827038-05-3 827038-06-4 827038-07-5
 827038-08-6 827038-09-7 827038-10-8
 827038-11-9 827038-12-0 827038-13-1
 827038-14-2 827038-15-3 827038-16-4
 827038-17-5 827038-18-6 827038-19-7
 827038-20-8 827038-21-9 827038-22-0
 827038-23-1 827038-24-2 827038-25-3
 827038-26-4 827038-27-5 827038-28-6
 827038-29-7 827038-30-8 827038-31-9
 827038-32-0 827038-33-1 827038-34-2
 827038-35-3 827038-36-4 827038-37-5
 827038-38-6 827038-39-7 827038-40-8
 827038-41-9 827038-42-0 827038-43-1
 827038-44-2 827038-45-3 827038-46-4
 827038-47-5 827038-48-6 827038-49-7
 827038-50-8 827038-51-9 827038-52-0
 827038-53-1 827038-54-2 827038-55-3
 827038-56-4 827038-57-5 827038-58-6
 827038-59-7 827038-60-8 827038-61-9
 827038-62-0 827038-63-1 827038-64-2
 827038-65-3 827038-66-4 827038-67-5
 827038-68-6 827038-69-7 827038-70-8
 827038-71-9 827038-72-0 827038-73-1
 827038-74-2 827038-75-3 827038-76-4
 827038-77-5 827038-78-6 827038-79-7
 827038-80-8 827038-81-9 827038-82-0
 827038-83-1 827038-84-2 827038-85-3
 827038-86-4 827038-87-5 827038-88-6
 827038-89-7 827038-90-8 827038-91-9
 827038-92-0 827038-93-1 827038-94-2
 827038-95-3 827038-96-4 827038-97-5
 827038-98-6 827038-99-7 827039-00-8
 827039-01-9 827039-02-0 827039-03-1
 827039-04-2 827039-05-3 827039-06-4
 827039-07-5 827039-08-6 827039-09-7
 827039-10-8 827039-11-9 827039-12-0
 827039-13-1 827039-14-2 827039-15-3
 827039-16-4 827039-17-5 827039-18-6
 827039-19-7 827039-20-8 827039-21-9
 827039-22-0 827039-23-1 827039-24-2
 827039-25-3 827039-26-4 827039-27-5
 827039-28-6 827039-29-7 827039-30-8
 827039-31-9 827039-32-0 827039-33-1
 827039-34-2 827039-35-3 827039-36-4
 827039-37-5 827039-38-6 827039-39-7
 827039-40-8 827039-41-9 827039-42-0
 827039-43-1 827039-44-2 827039-45-3
 827039-46-4 827039-47-5 827039-48-6
 827039-49-7 827039-50-8 827039-51-9
 827039-52-0 827039-53-1 827039-54-2
 827039-55-3 827039-56-4 827039-57-5
 827039-58-6 827039-59-7 827039-60-8
 827039-61-9 827039-62-0 827039-63-1
 827039-64-2 827039-65-3 827039-66-4
 827039-67-5 827039-68-6 827039-69-7
 827039-70-8 827039-71-9 827039-72-0
 827039-73-1 827039-74-2 827039-75-3
 827039-76-4 827039-77-5 827039-78-6
 827039-79-7 827039-80-8 827039-81-9
 827039-82-0 827039-83-1 827039-84-2
 827039-85-3 827039-86-4 827039-87-5
 827039-88-6 827039-89-7 827039-90-8
 827039-91-9 827039-92-0 827039-93-1
 827039-94-2 827039-95-3 827039-96-4
 827039-97-5 827039-98-6 827039-99-7
 827040-00-8 827040-01-9 827040-02-0
 827040-03-1 827040-04-2 827040-05-3
 827040-06-4 827040-07-5 827040-08-6
 827040-09-7 827040-10-8 827040-11-9
 827040-12-0 827040-13-1 827040-14-2
 827040-15-3 827040-16-4 827040-17-5
 827040-18-6 827040-19-7 827040-20-8
 827040-21-9 827040-22-0 827040-23-1
 827040-24-2 827040-25-3 827040-26-4
 827040-27-5 827040-28-6 827040-29-7
 827040-30-8 827040-31-9 827040-32-0
 827040-33-1 827040-34-2 827040-35-3
 827040-36-4 827040-37-5 827040-38-6
 827040-39-7 827040-40-8 827040-41-9
 827040-42-0 827040-43-1 827040-44-2
 827040-45-3 827040-46-4 827040-47-5
 827040-48-6 827040-49-7 827040-50-8
 827040-51-9 827040-52-0 827040-53-1
 827040-54-2 827040-55-3 827040-56-4
 827040-57-5 827040-58-6 827040-59-7
 827040-60-8 827040-61-9 827040-62-0
 827040-63-1 827040-64-2 827040-65-3
 827040-66-4 827040-67-5 827040-68-6
 827040-69-7 827040-70-8 827040-71-9
 827040-72-0 827040-73-1 827040-74-2
 827040-75-3 827040-76-4 827040-77-5
 827040-78-6 827040-79-7 827040-80-8
 827040-81-9 827040-82-0 827040-83-1
 827040-84-2 827040-85-3 827040-86-4
 827040-87-5 827040-88-6 827040-89-7
 827040-90-8 827040-91-9 827040-92-0
 827040-93-1 827040-94-2 827040-95-3
 827040-96-4 827040-97-5 827040-98-6
 827040-99-7 827041-00-8 827041-01-9
 827041-02-0 827041-03-1 827041-04-2
 827041-05-3 827041-06-4 827041-07-5
 827041-08-6 827041-09-7 827041-10-8
 827041-11-9 827041-12-0 827041-13-1
 827041-14-2 827041-15-3 827041-16-4
 827041-17-5 827041-18-6 827041-19-7
 827041-20-8 827041-21-9 827041-22-0
 827041-23-1 827041-24-2 827041-25-3
 827041-26-4 827041-27-5 827041-28-6
 827041-29-7 827041-30-8 827041-31-9
 827041-32-0 827041-33-1 827041-34-2
 827041-35-3 827041-36-4 827041-37-5
 827041-38-6 827041-39-7 827041-40-8
 827041-41-9 827041-42-0 827041-43-1
 827041-44-2 827041-45-3 827041-46-4
 827041-47-5 827041-48-6 827041-49-7
 827041-50-8 827041-51-9 827041-52-0
 827041-53-1 827041-54-2 827041-55-3
 827041-56-4 827041-57-5 827041-58-6
 827041-59-7 827041-60-8 827041-61-9
 827041-62-0 827041-63-1 827041-64-2
 827041-65-3 827041-66-4 827041-67-5
 827041-68-6 827041-69-7 827041-70-8
 827041-71-9 827041-72-0 827041-73-1
 827041-74-2 827041-75-3 827041-76-4
 827041-77-5 827041-78-6 827041-79-7
 827041-80-8 827041-81-9 827041-82-0
 827041-83-1 827041-84-2 827041-85-3
 827041-86-4 827041-87-5 827041-88-6
 827041-89-7 827041-90-8 827041-91-9
 827041-92-0 827041-93-1 827041-94-2
 827041-95-3 827041-96-4 827041-97-5
 827041-98-6 827041-99-7 827042-00-8
 827042-01-9 827042-02-0 827042-03-1
 827042-04-2 827042-05-3 827042-06-4
 827042-07-5 827042-08-6 827042-09-7
 827042-10-8 827042-11-9 827042-12-0
 827042-13-1 827042-14-2 827042-15-3
 827042-16-4 827042-17-5 827042-18-6
 827042-19-7 827042-20-8 827042-21-9
 827042-22-0 827042-23-1 827042-24-2
 827042-25-3 827042-26-4 827042-27-5
 827042-28-6 827042-29-7 827042-30-8
 827042-31-9 827042-32-0 827042-33-1
 827042-34-2 827042-35-3 827042-36-4
 827042-37-5 827042-38-6 827042-39-7
 827042-40-8 827042-41-9 827042-42-0
 827042-43-1 827042-44-2 827042-45-3
 827042-46-4 827042-47-5 827042-48-6
 827042-49-7 827042-50-8 827042-51-9
 827042-52-0 827042-53-1 827042-54-2
 827042-55-3 827042-56-4 827042-57-5
 827

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 745782-40-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827034-86-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 827034-88-8 CAPLUS


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827034-94-6 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[1S]-2-[1,1'-biphenyl]-4-yl-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-96-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(2-naphthalenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-98-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-(cyclohexyloxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-methylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-90-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-(phenylmethoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827034-92-4 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[1S]-2-[4-(2-butynyloxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-00-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(4-(4-methylpentyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-02-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(3,4-dimethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-04-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-chlorophenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-06-3 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-fluorophenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-08-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-pentylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-14-3 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-16-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2',4'-difluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-10-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-pyridinylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-12-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-chloro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B

Me


RN 827035-18-7 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-thienylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827035-20-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 827035-21-2 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyanophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-23-4 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-chlorophenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-25-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-nitrophenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827035-29-0 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-30-3 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(3-chlorophenyl)phenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-31-4 CAPLUS

CN D-erythro-Pentonic acid, 5-[(1S)-2-(4-butoxyphenyl)-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-27-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2-thienylethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-28-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(1,1-dimethylethyl)phenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-32-5 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-propoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-33-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-(2-propenyloxy)phenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-34-7 CAPLUS


CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-methoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

[illegible]


RN 827035-38-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-dodecenoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-40-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-11-phenyl-1-undecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CCCCCCCCCCCCCCCC(=O)C/C=C/[C@H](O)C(=O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O


RN 827035-45-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[(1R)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2, 4, 5-trideoxy-5-oxo-4-[[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

CCCCOC1=CC=C(C=C1)C[C@H](C(=O)O)N[C@@H](C(=O)O)[C@H](O)C[C@H](C(=O)O)C/C=C/C(C)CCCCCCCCC(C)C

RN 827035-46-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-{4-(3-methylbutoxy)phenyl}ethylamino]-4-[(1E)-11-cyclohexyl-9-oxo-11-tridecenyl]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



RN 827035-50-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(4-methoxyphenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 876344-57-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 876344-58-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-2,4,5-trideoxy-5-[[[(1S)-2-methoxy-1-[[4-(3-methylphenoxy)phenyl]methyl]-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 876344-59-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-10-hydroxy-9-oxo-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 876344-60-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 876344-61-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-9-hydroxy-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 876344-62-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-(aminocarbonyl)-5-[[[(1S)-1-carboxy-2-[4-[(3-


L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methyl-2-butenyl]oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 876344-63-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 876344-64-8 CAPLUS
 CN D-erythro-Pentonic acid, 4-[(1E)-9-[(2-aminoethoxy)imino]-1-hexadecenyl]-3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 876344-65-9 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-
 butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-9-(methoxyimino)-1-
 hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 876404-54-5 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-
 butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-
 hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:148778 CAPLUS
 DOCUMENT NUMBER: 144:63941
 TITLE: Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
 AUTHOR(S): Sakamoto, Hiroshi; Okamoto, Koichi; Aoki, Masahiro; Kato, Hideyuki; Katsume, Asao; Ohta, Atsunori; Takuu, Takuo; Shima, Nobuo; Aoki, Yuko; Arisawa, Mikio; Kohara, Michinori; Sudoh, Masayuki
 CORPORATE SOURCE: Kamakura Research Laboratories, Chugai Pharmaceutical Co. Ltd., Kamakura, Kanagawa, 247-8530, Japan
 SOURCE: Nature Chemical Biology (2005), 1(6), 333-337
 CODEN: NCBABT; ISSN: 1552-4450
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB An estimated 170 million individuals worldwide are infected with hepatitis C virus (HCV), a serious cause of chronic liver disease. Current interferon-based therapy for treating HCV infection has an unsatisfactory cure rate, and the development of more efficient drugs is needed. During the early stages of HCV infections, various host genes are differentially regulated, and it is possible that inhibition of host proteins affords a therapeutic strategy for treatment of HCV infection. Using an HCV subgenomic replicon cell culture system, here we have identified, from a secondary fungal metabolite, a lipophilic long-chain base compound, NA255 (1), a previously unknown small-mol. HCV replication inhibitor. NA255 prevents the de novo synthesis of sphingolipids, major lipid raft components, thereby inhibiting serine palmitoyltransferase, and it disrupts the association among HCV nonstructural (NS) viral proteins on the lipid rafts. Furthermore, we found that NS5B protein has a sphingolipid-binding motif in its mol. structure and that the domain was able to directly interact with sphingomyelin. Thus, NA255 is a new anti-HCV replication inhibitor that targets host lipid rafts, suggesting that inhibition of sphingolipid metabolism may provide a new therapeutic strategy for treatment of HCV infection.
 IT 745782-39-2P, NA 255
 RI: DMA (Drug mechanism of action); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
 (host sphingolipid biosynthesis as target for hepatitis C virus therapy)
 RN 745782-39-2 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methyl-2-
 butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-
 hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:529464 CAPLUS
 DOCUMENT NUMBER: 143:193833
 TITLE: Ester Dienolate [2,3]-Wittig Rearrangement in Natural Product Synthesis: Diastereoselective Total Synthesis of the Triester of Viridifungin A, A2, and A4
 AUTHOR(S): Pollex, Annett; Millet, Agnes; Mueller, Jana; Hiersemann, Martin; Abraham, Lars
 CORPORATE SOURCE: Institut fuer Organische Chemie, Technische Universitaet Dresden, Dresden, 01062, Germany
 SOURCE: Journal of Organic Chemistry (2005), 70(14), 5379-5391
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:193833
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB An ester dienolate [2,3]-Wittig rearrangement was utilized to access the alkylated citric acid skeleton I that is characteristic for the viridifungins and other members of the alkyl citrate family of secondary natural products. The [2,3]-sigmatropic rearrangement of II provided the rearrangement product I in moderate yield and with very good diastereoselectivity. A Julia-Kocienski olefination efficiently served to connect the polar head III with the lipophilic tail, e.g. IV of the viridifungins. Amide formation between the racemic viridifungin precursors, e.g. V, and the enantiomerically pure amino acid L-tyrosine

Me ester followed by preparative reversed-phase HPLC provided the iso-Pr di-Me ester of viridifungin A (VI), A2, and A4 as well as nonnatural diastereomers.
 IT 777891-06-2P 861997-63-9P 861997-92-4P
 861997-93-5P 861997-94-6P 861997-95-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (diastereoselective total synthesis of the triester of viridifungin

A, A2, and A4 via ester dienolate [2,3]-Wittig rearrangement)
 RN 777891-06-2 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861997-63-9 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-D-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 861997-92-4 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-octadecenyl]-D-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 861997-93-5 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-octadecenyl]-L-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 861997-94-6 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-2-(1E)-1-hexadecenyl-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-D-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 861997-95-7 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-2-(1E)-1-hexadecenyl-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-L-erythro-pentonoyl]-, methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:45825 CAPLUS
 DOCUMENT NUMBER: 143:115373
 TITLE: Total synthesis of viridiodfungin A
 AUTHOR(S): Morokuma, Kenji; Takahashi, Keisuke; Ishihara, Jun; Hatakeyama, Susumi
 CORPORATE SOURCE: Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, 852-8521, Japan
 SOURCE: Chemical Communications (Cambridge, United Kingdom) (2005), (17), 2265-2267
 CODEN: CHCOFS; ISSN: 1359-7345
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:115373
 GI




AB Viridiodfungin A (I), a member of amino alkyl citrate antibiotics from *Trichoderma viride*, was enantioselectively synthesized in naturally occurring form for the first time, employing regio- and stereoselective opening of the chiral glycidate with vinylmagnesium bromide and alkene cross metathesis of the citric acid core and hexadec-15-en-8-one as key steps.

IT 147023-34-5P, (-)-Viridiodfungin A
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (total synthesis of viridiodfungin A via Sharpless asym. epoxidn., regio- and stereoselective ring opening of a chiral glycidate and cross metathesis reactions)

RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1E)-1-carboxy-2-(4-hydroxyphenylethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.


L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 857285-37-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of viridiodfungin A via Sharpless asym. epoxidn., regio- and stereoselective ring opening of a chiral glycidate and cross metathesis reactions)

RN 857285-37-1 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-5-O-(1,1-dimethylethyl)-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-erythro-pentonoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:55191 CAPLUS
 DOCUMENT NUMBER: 142:134920
 TITLE: Preparation of phenylalanine derivatives as anti-HCV agents
 INVENTOR(S): Sudoh, Masayuki; Takuda, Takuo; Masubuchi, Miyako; Kawasaki, Kenichi; Murata, Takeshi; Watanabe, Fumio; Fukuda, Hiroshi; Komiyama, Susumu; Hayase, Tadatsugu
 PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005372	A1	20050120	WO 2004-JP9803	20040709
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RN:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004255633	A1	20050120	AU 2004-255633	20040709
CA 2531790	A1	20050120	CA 2004-2531790	20040709
EP 1661882	A1	20060531	EP 2004-747271	20040709
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1819990	A	20060816	CN 2004-80019645	20040709
BR 2004012459	A	20060107	BR 2004-12459	20040709
NO 2005005986	A	20060213	NO 2005-5986	20051216
US 2006194870	A1	20060831	US 2005-563089	20051230
JP 2006232852	A	20060907	JP 2006-143804	20060524
PRIORITY APPLN. INFO.:			JP 2003-272420	A 20030709
			JP 2003-34056	A 20030212
			JP 2005-504986	A3 20040212
			WO 2004-JP9803	W 20040709

OTHER SOURCE(S): MARPAT 142:134920
 GI

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The title compds. I (wherein A = (CH₂)_n; n = 0-10; B = CH₂, CO, CH(OH), CH(NH₂), or (un)substituted C(=NOH); D = H or (un)substituted alkyl; E =

H or alkyl; G = H or (un)substituted alkyl; R₁-R₃ = independently alkyl, alkenyl, alkynyl, (un)substituted OH, or NH₂), or prodrugs or pharmaceutically acceptable salts thereof are prepared as HCV replication inhibitors for the treatment of viral infectious diseases, especially liver

diseases attributable to HCV infection. For example, the compound II was prepared in a multi-step synthesis. II inhibited replicon with IC₅₀ of 0.002 μM in cow.

IT 827034-86-6P 827034-88-8P 827034-90-2P
 827034-92-4P 827034-94-6P 827034-96-8P
 827034-98-0P 827035-00-7P 827035-02-9P
 827035-04-1P 827035-06-3P 827035-08-5P
 827035-10-9P 827035-12-1P 827035-14-3P
 827035-16-5P 827035-18-7P 827035-20-1P
 827035-21-2P 827035-23-4P 827035-25-6P
 827035-27-8P 827035-29-0P 827035-31-2P
 827035-33-6P 827035-35-8P 827035-37-0P
 827035-39-2P 827035-41-4P 827035-43-6P
 827035-45-0P 827035-47-2P 827035-49-4P
 827035-51-6P 827035-53-8P 827035-55-0P
 827035-57-2P 827035-59-4P 827035-61-6P
 827035-63-8P 827035-65-0P 827035-67-2P
 827035-69-4P 827035-71-4P 827035-73-6P
 827035-75-8P 827035-77-0P 827035-79-2P
 827035-81-4P 827035-83-6P 827035-85-8P

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

827035-84-7P 827035-85-8P 827035-86-9P
827035-87-0P 827035-88-1P 827035-89-2P
827035-90-3P 827035-91-6P 827035-93-8P
827035-95-0P 827035-97-2P 827035-99-4P
827036-01-1P 827036-03-3P 827036-05-5P
827036-07-7P 827036-09-9P 827036-10-2P
827036-11-3P 827036-12-4P 827036-13-5P
827036-14-6P 827036-15-7P 827036-16-8P
827036-17-9P 827036-18-0P 827036-19-1P
827036-20-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of phenylalanine derivs. as anti-HCV agents)

RN 827034-86-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 827034-88-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-methylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827034-96-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(2-naphthalenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827034-98-0 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(cyclohexyloxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-00-7 CAPLUS


CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-methylpentyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827034-90-2 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(phenylmethoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827034-92-4 CAPLUS

CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-(2-butyloxy)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827034-94-6 CAPLUS

CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[1,1'-biphenyl]-4-yl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-02-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3,4-dimethoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-04-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(4-chlorophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-06-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-fluorophenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-08-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-pentylphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-10-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-pyridinyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-16-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(2',4'-difluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

Me

RN 827035-18-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-thienyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-12-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-chloro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-14-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-20-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-21-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-cyanophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-23-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-(4-chlorophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-25-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-nitrophenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-27-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(2-thienyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-30-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(3-chlorophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-31-4 CAPLUS
CN D-erythro-Pentonic acid, 5-[[[(1S)-2-(4-butoxyphenyl)-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 827035-32-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-28-9 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(1,1-dimethylethyl)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-29-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-chloro(1,1'-biphenyl)-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-33-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(2-propenyloxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-34-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-methoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-35-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-11-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-36-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-42-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-heptadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-43-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-4-[(1E)-14-methyl-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-45-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-38-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-dodecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-40-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-11-phenyl-1-undecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-41-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1,15-hexadecadienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-46-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-methylbutoxy)phenyl]ethyl]amino]-4-[(1E)-11-cyclohexyl-9-oxo-1-undecenyl]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-48-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(4-methylphenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 827035-50-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1E)-1-carboxy-2-[4-(4-methoxyphenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-51-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(4-(trifluoromethyl)phenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-53-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-methylphenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 827035-54-1 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-(trifluoromethyl)phenoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-56-3 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(4-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-B

OHMe
RN 827035-57-4 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(3-methyl[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-59-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(3-(trifluoromethyl)[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-B

CF3
RN 827035-61-0 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(3-methyl[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-62-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-methoxy[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 827035-64-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(3-fluorophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-64-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(2'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

OMe

RN 827035-63-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827035-66-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3'-fluoro[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B

NMe2


RN 827035-69-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(phenylamino)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-70-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(cyanophenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-67-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(dimethylamino)phenoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-68-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(dimethylamino)[1,1'-biphenyl]-4-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-71-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(4-cyano-1,1'-biphenyl)-4-yl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B

CN

RN 827035-72-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(4-morpholinylphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-73-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(6-methoxy-3-pyridinylphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B

OMe

RN 827035-74-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(dimethylamino)sulfonyl]-[1,1'-biphenyl]-4-yl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-B



RN 827035-75-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(methylphenylamino)phenyl]ethylamino)-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-76-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(5-pyridinylphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-77-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4'-(methylthio)-[1,1'-biphenyl]-4-yl]ethylamino)-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B

SMe

RN 827035-78-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(5-methoxy-3-pyridinylphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-79-0 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-80-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-82-5 CAPLUS
 CN D-erythro-Pentonic acid, 5-[(1S)-2-[4-(3-aminopropoxy)phenyl]-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-83-6 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-84-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-(dimethylamino)propoxy)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




PAGE 1-A

PAGE 1-B



RN 827035-81-4 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-methoxy-5-pyrimidinyl)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

PAGE 1-B




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-85-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(3-pyridinylmethoxy)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 827035-86-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-(2-(4-morpholinyl)ethoxy)phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827035-87-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[2-(1-piperazinyl)ethoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-88-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[3-[(3-pyridinylmethyl)amino]propoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 1-A



RN 827035-89-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B




RN 827035-90-5 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-azidophenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-91-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]methyl]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-93-8 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(methylsulfonyl)amino]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827035-95-0 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-(acetamidophenyl)-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827035-97-2 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[4-(aminomethyl)phenyl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827035-99-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(ethoxycarbonyl)-1H-1,2,3-triazol-1-yl]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-01-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(ethoxycarbonyl)-1H-1,2,3-triazol-1-yl]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

PAGE 1-B




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827036-09-9 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[1,1'-biphenyl]-4-yl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-10-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-7-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-11-3 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-[1,1'-biphenyl]-4-yl]-1-carboxyethyl]amino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-03-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[3-(pyridinyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-05-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-15-fluoro-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-07-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(3-methylbutoxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-15-methoxy-9-oxo-1-pentadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 827036-12-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(phenoxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-pentadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 827036-13-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(2-hexyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-14-6 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(2-propynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 827036-15-7 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(4-pentynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 827036-16-8 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(3-pentynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.


RN 827036-19-1 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(2-decynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 1-B



RN 827036-20-4 CAPLUS


CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(6,6-dimethyl-2,4-heptadiynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827036-17-9 CAPLUS

CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-[(4-(diethylamino)-2-butyryloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

PAGE 1-B




RN 827036-18-0 CAPLUS


CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[4-(2-pentynyloxy)phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

IT 827036-33-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylalanine derivs. as anti-HCV agents)


RN 827036-33-9 CAPLUS

CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-[(1,1-dimethylethoxy)carbonyl]-

5-[[[(1S)-2-[(1,1-dimethylethoxy)-2-oxo-1-[(4-phenoxyphenyl)methyl]ethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 10 of 22 CAPLUS COPYRIGHT 2007 ACS on STM
ACCESSION NUMBER: 2004:701987 CAPLUS
DOCUMENT NUMBER: 141:230667
TITLE: Remedy for viral disease
INVENTOR(S): Aoki, Masahiro; Kato, Hideyuki; Sudoh, Masayuki;
Tsukuda, Takuo; Masubuchi, Miyako; Kawasaki, Kenichi
PATENT ASSIGNEE(S): Ectei Seiyaku Kabushiki Kaisha, Japan
SOURCE: CT Int. Appl., 98 pp.
COST: P1402
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

Inventors

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071503	A1	20040826	WO 2004-JP1498	2004062112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RW, SA, SE, SG, SI, SK, SL, SM, SN, ST, SV, SW, SY, TD, TH, TJ, TM, TN, TR, TT, TW, UG, UA, UZ, VC, VE, VN, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, GM, LR, MR, NE, SN, TD, TG				
CA 2004211850	A1	20040826	CA 2004-211850	2004062112
AU 2515370	A1	20040826	AU 2004-2515370	2004062112
EP 1593378	A1	20050119	EP 2004-710509	2004062112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004070140	A	20060207	BR 2004-070140	2004062112
CN 1835744	A	20060620	CN 2004-80004095	2004062112
US 2006217434	A	20060928	JP 2005-544896	20050808
JP 200632852	A	20060907	JP 2006-143804	20060524
PRIORITY APPLN. INFO.:			JP 2003-34056	A 20030212
			JP 2003-272420	A 20030709
			JP 2005-504986	A3 2004062112
			WO 2004-JP1498	W 2004062112


8/8/05
2/12/04
2/12/03

OTHER SOURCE(S): MARPAT 141:230667
AB It is intended to provide a medicinal composition for preventing or treating viral infection. A medicinal composition containing a compound, which has an extremely potent anti-HCV activity and an HCV amplification inhibitory effect and shows little cytotoxicity in vivo, is highly useful as a preventive/remedy for HCV.
IT 745782-39-2P
RI: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); STO (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(remedy for viral disease)

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 745782-39-2 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[(1S)-1-carboxy-2-[4-[(3-methyl-2-
 butenyl)oxy]phenyl]ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-
 hexadecyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



IT 744208-61-5P 744208-62-6P 744208-63-7P
744208-64-8P 744208-65-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); PRP (Properties); PUR (Purification or recovery); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(remedy for viral disease)

RN 744208-61-5 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[1(1S)-1-carboxy-2-[[4-[(3-methyl-2-
 butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-
 hexadecyl)-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-62-6 CAPLUS
 CN D-erythro-Pentonic acid,
 3-C-carboxy-5-[[{(1S)-2-methoxy-1-[[4-{(3-methyl-2-
 butenyl)oxy]phenyl]methyl]-2-oxoethyl]amino]-2,4,5-trideoxy-5-oxo-4-{9-oxo-1-
 hexadecenyl}-, 1-methyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-63-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2, 4, 5-trideoxy-4-{9-hydroxy-1-hexadecenyl}-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 744208-64-8 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[1S]-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 744208-65-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(3-methyl-2-butenyl)oxy]phenyl]ethyl]amino]-2,4,5-trideoxy-4-(10-hydroxy-9-oxo-1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




IT 744208-68-2P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (remedy for viral disease)

RN 744208-68-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 744208-69-3 CAPLUS
 CN D-erythro-Pentamide, N5-[[[(1S)-2-amino-1-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-2-oxoethyl]amino]-3-C-carboxy-2,4,5-trideoxy-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 744208-70-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxohexadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 744208-66-0P 744208-67-1P 744208-69-3P
 744208-70-6P 744208-71-7P 744208-72-8P
 744208-73-9P 744208-74-0P 744208-75-1P
 744208-76-2P 744208-77-3P 744208-78-4P
 744208-92-2P 745782-40-5P
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (remedy for viral disease)

RN 744208-66-0 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-(3-methylbutoxy)phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 744208-67-1 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-[(3-methyl-2-butenyl)oxy]phenyl)ethyl]amino]-2,4,5-trideoxy-4-(9-hydroxy-1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 744208-71-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-[(3-methyl-2-butenyl)oxy]phenyl)ethyl]amino]-2,4,5-trideoxy-4-(1-hexadecenyl)-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 744208-72-8 CAPLUS
 CN D-erythro-Pentonic acid, 4-[9-[(2-aminoethoxy)imino]-1-hexadecenyl]-3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-[(3-methyl-2-butenyl)oxy]phenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 1-B




RN 744208-73-9 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[(4-[(3-methyl-2-butenyl)oxy]phenyl)ethyl]amino]-2,4,5-trideoxy-4-[9-(methoxyimino)-1-hexadecenyl]-5-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry unknown.

RN 744208-74-0 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-(4-butoxyphenyl)-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]


Absolute stereochemistry.
Double bond geometry unknown.

RN 744208-75-1 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-2-(4-(2-butoxyloxy)phenyl)-1-carboxyethylamino]-3-C-carboxy-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]


Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 744208-78-4 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-methoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry unknown.


RN 744208-92-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(3,4-dimethoxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry unknown.


RN 745782-40-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.


L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 744208-76-2 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(2-propenyloxy)phenyl)ethylamino]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry unknown.


RN 744208-77-3 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-(2-propoxyphenyl)ethylamino)-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry unknown.

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 744208-91-1P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (Remedy for viral disease)
 RN 744208-91-1 CAPLUS
 CN D-erythro-Pentonic acid, 5-[[[(1S)-1-[[4-(2-butoxyloxy)phenyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethylamino]-3-C-[(1,1-dimethylethoxy)carbonyl]-2,4,5-trideoxy-5-oxo-4-(9-oxo-1-hexadecenyl)]-(9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry unknown.


L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:689188 CAPLUS
 DOCUMENT NUMBER: 141:366432
 TITLE: Total synthesis of (3S,4S,2'S)- and (3R,4R,2'S)-viridiofungin A triester
 AUTHOR(S): Pollex, Annett; Abraham, Lars; Mueller, Jana; Wiersemann, Martin
 CORPORATE SOURCE: Institut fuer Organische Chemie, Technische Universitaet Dresden, Dresden, D-01062, Germany
 SOURCE: Tetrahedron Letters (2004), 45(37), 6915-6918
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:366432
 AB The total synthesis of an alkylcitrate secondary metabolite from the fungi *Trichoderma viride* is described. An ester dienolate [2,3]-Wittig rearrangement and a S.Julia-Kocienski olefination served as key C/C-connecting transformations. The afforded two diastereomers, were separated by preparative reversed-phase HPLC to provide the (3S,4S,2'S)-viridiofungin A triester and the (3R,4R,2'S)-viridiofungin A triester as single diastereoisomers and enantiomers. The highly convergent synthesis consists of a longest linear sequence of 17 steps.
 IT 777891-06-2P 777891-07-3P
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
 (total synthesis and resolution of viridiofungin A triester and its unnatural diastereoisomer via diastereoselective ester dienolate Wittig rearrangement, Julia-Kocienski olefination and HPLC)
 RN 777891-06-2 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-erythro-pentonyl]-, methyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



L3 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:66706 CAPLUS
 DOCUMENT NUMBER: 132:202567
 TITLE: Isolation and characterization of novel inhibitors of sphingolipid synthesis: australifungin, viridiofungin, rustmicin, and khafrefungin
 AUTHOR(S): Mandala, Suzanne M.; Harris, Guy H.
 CORPORATE SOURCE: Department of Infectious Disease, Merck Research Laboratories, Rahway, NJ 07065-4607, USA
 SOURCE: Methods in Enzymology (2000), 311(Sphingolipid Metabolism and Cell Signaling, Part A), 335-348
 CODEN: MENZAU; ISSN: 0046-6879
 PUBLISHER: Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A method to identify sphingolipids and a detailed protocol for the isolation of australifungin are described. Brief descriptions of the isolation of viridiofungin, khafrefungin, and rustmicin are included. The biol. activity of the inhibitors of sphingolipid synthesis is examined by ceramide synthase, serine palmitoyltransferase, and inositol phosphoceramide synthase inhibition tests. (c) 2000 Academic Press.
 IT 147023-34-5P, Viridiofungin A
 RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery);
 ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
 (isolation and characterization of novel inhibitors of sphingolipid synthesis)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[1S]-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


R₁=OH
 R₂=OH
 R₃=OH

n = 6
 D = heptyl

Searched by Jason M. Nolan, Ph.D.

L3 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 777891-07-3 CAPLUS
 CN L-Tyrosine, N-[2,4-dideoxy-5-O-methyl-3-C-[(1-methylethoxy)carbonyl]-5-C-oxo-2-[(1E)-9-oxo-1-hexadecenyl]-L-threo-pentonyl]-, methyl ester (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:282451 CAPLUS
 DOCUMENT NUMBER: 131:19258
 TITLE: Synthesis of viridiofungin A and its absolute structure
 AUTHOR(S): Esumi, T.; Iwabuchi, Y.; Irie, H.; Hatakeyama, S.
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagasaki University, Nagasaki, Japan
 SOURCE: Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1997), 38th, 409-414
 CODEN: TYKYDS
 PUBLISHER: Nippon Kagakai
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 GI



AB Viridiofungin A was isolated from a strain of *Trichoderma viride* Pers. (Fungi, Hyphomycetes) together with viridiofungin B and C after screening for substances that exhibit cholesterol lowering activity. These viridiofungins, a novel family of squalene synthase inhibitors, have unique structures consisting of a common citric acid moiety having C-16 long chain and an aromatic amino acid residue such as tyrosine, phenylalanine, and tryptophan. However, the absolute structures of these compds. have not been determined yet. We describe the first synthesis of viridiofungin A tri-Me ester which allowed us to determine its absolute configuration to be 3S,4S,2'S. Katsuki-Sharpless asym. epoxidn. of the trisubstituted allylic alc. [trans-MPPOCH₂CH₂C(CH₂OMPM):CHCH₂OH; MPM = p-methoxybenzyl] followed by regio- and stereoselective opening of

Page 33

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(I) to give the diol (II) from which two epimeric aldehydes (III and IV) were prepd. selectively. Upon attachment of the long chain portion by Wittig olefination reaction followed by functional group transformations, the aldehyde III and IV gave the alc. (V; R = H, R1 = CH2OH) and (V; R = CH2OH, R1 = H) resp. After Jones oxidn. of V (R = H, R1 = CH2OH), the resulting carboxylic acid was condensed with L- and D-tyrosine Me ester

to give (3S,4S,2'S)-viridifungin A tri-Me ester (V; R = H, R1 = L-Tyr-OMe) and (3S,4S,2'R)-viridifungin A tri-Me ester (V; R = H, R1 = D-Tyr-OMe) (viridifungin A deriv.). Similarly, (3S,4R,2'S)-viridifungin A tri-Me ester (V; R = L-Tyr-OMe, R1 = H) and (3S,4R,2'R)-viridifungin A tri-Me ester (V; R = D-Tyr-OMe, R1 = H) were also synthesized from V (R = H, R1 =

CH2OH). Now we can conclude that the abs. configuration of natural viridifungin A is 3S,4S,2'S by comparison (1H NMR and TLC) of four synthetic samples with natural viridifungin A tri-Me ester in addn. to information that the tyrosine-configuration is L.


IT 204524-70-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of viridifungin A having cholesterol-lowering and squalene synthase inhibitory activity and its absolute structure)

RN 204524-70-9 CAPLUS

CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1R)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




IT 147023-37-8P 204524-71-0P 204524-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(viridifungin A stereoisomer; total synthesis of viridifungin A having cholesterol-lowering and squalene synthase inhibitory activity and its absolute structure)

RN 147023-37-8 CAPLUS


CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 204524-71-0 CAPLUS

CN L-threo-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 204524-72-1 CAPLUS

CN L-threo-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1R)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
1999:7961 CAPLUS

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:


LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856755	A1	19981217	WO 1998-JP2530	19980609
W: AU, BG, CA, CN, CZ, HU, JP, KR, MX, NO, PL, RO, SK, US, AM, AZ, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9875520	A	19981230	AU 1998-75520	19980609
EP 1002793	A1	20000524	EP 1998-923171	19980609
EP 1002793	B1	20030924		
ES 2209140	T3	20040616	ES 1998-923171	19980609
US 6303350	B1	20011016	US 2000-445543	20000307
PRIORITY APPL. INFO.:			JP 1997-168011	A 19970609
			WO 1998-JP2530	W 19980609

GI



NOT HCV

AB Novel physiol. active substances TKR2449 analogs (I: R1, R2, and R3 are the same or different and each represents hydrogen or C alkyl; and R4 represents linear or branched C alkyl or alkenyl) useful as remedies for fungal infection or immunol. diseases. are manufactured with Aureobasidium


IT 217648-17-4P, TKR 2449

RL: BPN (Biosynthetic preparation); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(physiol. active substances TKR2449, process for producing same and microorganism)

RN 217648-17-4 CAPLUS


L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Butanedioic acid, 2-[[1-[[[1-carboxy-2-[[4-[[3-methyl-2-butenyl]oxy]phenyl]ethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy-(9CI) (CA INDEX NAME)

Double bond geometry unknown.
 Currently available stereo



IT 217648-18-5P, TKR 2449 methyl ester
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (physiol. active substances TKR2449, process for producing same and microorganism)
 RN 217648-18-5 CAPLUS
 CN Butanedioic acid, 2-hydroxy-2-[[1-[[[2-methoxy-1-[[4-[[3-methyl-2-butenyl]oxy]phenyl]methyl]-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Double bond geometry unknown.
 Currently available stereo shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 1998:107242 CAPLUS
 DOCUMENT NUMBER: 128:230160
 TITLE: Synthesis of viridifungin A trimethyl ester and determination of the absolute structure of viridifungin A
 AUTHOR(S): Tsunai, Tomoyuki; Iwabuchi, Yoshiharu; Irie, Hiroshi; Hatakeyama, Susumi
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagasaki University, Nagasaki, 852, Japan
 SOURCE: Tetrahedron Letters (1998), 39(8), 877-880
 PUBLISHER: CODEN: TETLEA; ISSN: 0040-4039
 DOCUMENT TYPE: Elsevier Science Ltd.
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 GI: CASREACT 128:230160




AB Four diastereoisomeric tri-Me esters of viridifungin A, a member of novel family of aminoacyl alkyl citrate compds., were synthesized in a highly stereoselective manner and the absolute configuration of natural viridifungin A was determined to be 3S,4S,2'S as depicted in triacid I.

IT 147023-34-5
 RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
 (absolute configuration of viridifungin A via asym. total synthesis of its tri-Me ester)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-[[4-hydroxyphenyl]methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[[1E]-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 147023-37-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (absolute configuration of viridifungin A via asym. total synthesis of its tri-Me ester)
 RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[[4-hydroxyphenyl]methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[[1E]-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



IT 204524-70-9P 204524-71-0P 204524-72-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (absolute configuration of viridifungin A via asym. total synthesis of its tri-Me ester)
 RN 204524-70-9 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1R)-1-[[4-hydroxyphenyl]methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[[1E]-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 204524-71-0 CAPLUS
 CN L-threo-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[[4-hydroxyphenyl]methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[[1E]-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 204524-72-1 CAPLUS
 CN L-threo-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1R)-1-[[4-hydroxyphenyl]methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[[1E]-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.

L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:308114 CAPLUS
DOCUMENT NUMBER: 127:31288
TITLE: Viridifungins, novel inhibitors of sphingolipid synthesis
AUTHOR(S): Mandala, Suzanne M.; Thornton, Rosemary A.; Frommer, Beth R.; Dreikorn, Sarah; Kurtz, Myra B.
CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Journal of Antibiotics (1997), 50(4), 339-343
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Viridifungins are broad spectrum antifungal agents that inhibit the squalene synthase in vitro, but do not specifically inhibit fungal ergosterol synthesis in whole cells, indicating a different mode of action for antifungal activity. In this report, we show that viridifungins are potent in vitro inhibitors of serine palmitoyltransferase, the first committed enzyme in sphingolipid biosynthesis, and their antifungal activity is due to inhibition of sphingolipid synthesis. Addnl. related components with the same mode of action were isolated from the producing culture, Trichoderma viride, and inhibition of the serine palmitoyltransferase and antifungal activity is presented.
IT 147023-35-6, Viridifungin B
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antifungal activity of viridifungins with phytosphingosine or stearylamine)
RN 147023-35-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-phenylethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry as shown.




IT 147023-34-5, Viridifungin A 147023-36-7, Viridifungin C 158589-77-6, Viridifungin A4 158589-79-8, Viridifungin B2 158589-81-2, Viridifungin A1 158589-82-3, Viridifungin A3 158589-84-5, Viridifungin A2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antifungal activity of viridifungins with phytosphingosine or stearylamine)
RN 147023-35-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-phenylethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)]

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
study, unclassified); BIOL (Biological study) (viridifungins, novel inhibitors of sphingolipid synthesis)


RN 147023-34-5 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




RN 147023-36-7 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.
Double bond geometry as shown.




RN 158589-77-6 CAPLUS
CN Butanedioic acid, 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-2-[[1-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)]


L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-79-8 CAPLUS
CN Butanedioic acid, 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)]




RN 158589-81-2 CAPLUS
CN Butanedioic acid, 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-2-[[1-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)]




RN 158589-82-3 CAPLUS
CN Butanedioic acid, 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-2-[[1-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)]

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 130389-84-5 CAPLUS
 CN Butanedioic acid,
 2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




IT 160065-77-0P, Viridiodfungin A 1-methyl ester 160065-78-1P
 , Viridiodfungin A 1'-methyl ester 160065-79-2P, Viridiodfungin A
 1,1'-dimethyl ester 190718-93-5P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (viridiodfungins, novel inhibitors of sphingolipid synthesis)
 RN 160065-77-0 CAPLUS
 CN Butanedioic acid,
 2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 190718-93-5 CAPLUS
 CN Butanedioic acid,
 2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxoheptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Currently available stereo shown.




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 160065-78-1 CAPLUS
 CN Butanedioic acid,
 2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)




RN 160065-79-2 CAPLUS
 CN Butanedioic acid,
 2-[[1-[[[1-carboxy-2-(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:308113 CAPLUS
 DOCUMENT NUMBER: 127:2922
 TITLE: Antimicrobial activity of viridiodfungins
 AUTHOR(S): Onishi, J. G.; Milligan, J. A.; Basilio, A.; Bergstrom, J.; Curotto, J.; Huang, L.; Mainz, M.; Nallin-Omstead, M.; Pelaez, F.; Rew, D.; Salvatore, M.; Thompson, J.; Vicente, F.; Kurtz, M. B.
 CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
 SOURCE: Journal of Antibiotics (1997), 50(4), 334-338
 PUBLISHER: CODEN: JANTA; ISSN: 0021-8820
 DOCUMENT TYPE: Japan Antibiotics Research Association
 LANGUAGE: Journal
 AB A family of aminoacyl alkyl citrate compds. called viridiodfungins, are novel squalene synthase inhibitors. The compds. have broad spectrum fungicidal activity but lack antibacterial activity. Although the compds. inhibit squalene synthase, the first committed step in ergosterol biosynthesis, results presented show that inhibition of fungal growth is not related to inhibition of ergosterol synthesis.
 IT 147023-34-5, Viridiodfungin A 147023-35-6, Viridiodfungin B 147023-36-7, Viridiodfungin C
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (viridiodfungins: antimicrobial activity)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996-4701 CAPLUS
 DOCUMENT NUMBER: 124:139477
 TITLE: New fungal metabolites as potential antihypercholesterolemics and anticancer agents
 AUTHOR(S): Huang, Leeyuan; Lingham, Russell B.; Harris, Guy H.; Singh, Sheo B.; Dufresne, Claude; Mallin-Omstead, Mary; Bills, Gerald F.; Mojena, Marina; Sanchez, Manuel; et al.
 CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Canadian Journal of Botany (1995), 73(Suppl. 1, Sect. E-H, Fifth International Mycological Congress, Sect. E-H, 1994), S898-S906
 CODEN: CJBOW; ISSN: 0008-4026
 PUBLISHER: National Research Council of Canada
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Several potent inhibitors of squalene synthetase have been discovered. Zaragasic acid A is produced by several fungi; zaragasic acid B is produced by several strains of *Sporormiella intermedia*; zaragasic acids C, E, and F are produced by *Leptodontidium elatius*; zaragasic acids D and D2 are produced by *Amauroascus niger*. L-731,120 and L-731,128 are minor components and coproduced with zaragasic acids A and B, resp. Viridifungins A, B, and C are produced by *Trichoderma viride*. Viridifungin A is also produced by an unidentified sterile fungus. Several of the zaragasic acids are also potent inhibitors of farnesyl-protein transferase (FPTase). Inhibitors of FPTase may act as potential anticancer drugs. Chaetomelic acids A and B are produced by a fungus, *Chaetomella acutiseta*, while fusidienol is produced by *Fusidium griseum*. All three compds. are potent inhibitors of FPTase. Our experiences suggest that many novel inhibitors of both squalene synthase and FPTase are produced within a diverse phylogenetic array of filamentous fungi. Several of the zaragasic acids are potent inhibitors of both FPTase and squalene synthetases. This is consistent with our observations that zaragasic acids and chaetomelic acids share some structural similarity.


IT 147023-34-5, Viridifungin A 147023-35-6, Viridifungin B 147023-36-7, Viridifungin C
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)
 (new fungal metabolites inhibiting squalene synthetases and farnesyl-protein transferase as potential antihypercholesterolemics and anticancer agents)

RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:261315 CAPLUS
 DOCUMENT NUMBER: 122:54157
 TITLE: Biologically active compounds isolated from aerobic fermentation of *Trichoderma viride*
 INVENTOR(S): Harris, Guy H.; Zink, Deborah; Jones, E. Tracy T.; Kong, Yu L.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 18 pp. Cont.-in-part of U.S. Ser. No. 739,758, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5364948	A	19941115	US 1993-15498	19930209
WO 9418157	A1	19940818	WO 1994-US792	19940125
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9462315	A	19940829	AU 1994-62315	19940125
PRIORITY APPLN. INFO.:			US 1991-739758	B2 19910802
			US 1992-907730	B2 19920709
			US 1993-15498	A 19930209
			WO 1994-US792	W 19940125

OTHER SOURCE(S): MARPAT 122:54157
 AB This invention relates to compds. isolated from an aerobic fermentation of *T. viride* MF5628, ATCC 74084, which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. These compds. are also potent antitumor agents. Admin., they inhibit farnesyl protein transferase and translocation of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining these compds.

IT 147023-34-5P 147023-35-6P 147023-37-8P
 158589-77-6P 158589-79-8P 158589-80-1P
 158589-82-3P 158589-84-5P 158589-85-6P
 158589-86-7P 160065-77-0P 160065-78-1P
 160065-79-2P 160065-80-5P 160065-81-6P
 RI: BMF (Bioindustrial manufacture); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (biol. active compds. isolated from aerobic fermentation of *Trichoderma viride*)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 147023-35-6 CAPLUS
CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 147023-37-8 CAPLUS
CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-77-6 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-(4-hydroxyphenyl)ethyl]amino)carbonyl]-10-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-79-8 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-phenylethyl)amino]carbonyl]-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-80-1 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-82-3 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-84-5 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-85-6 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-86-7 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-phenylethyl)amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 160065-77-0 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy-, 4-methyl ester (9CI) (CA INDEX NAME)




RN 160065-78-1 CAPLUS
CN Butanedioic acid, 2-[1-[[[(1-carboxy-2-(4-hydroxyphenyl)methyl)-2-methoxy-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 160065-79-2 CAPLUS
 CN Butanedioic acid,
 2-hydroxy-2-[1-[[[1-[(4-hydroxyphenyl)methyl]-2-methoxy-
 2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-, 4-methyl ester (9CI)
 (CA INDEX NAME)



RN 160065-80-3 CAPLUS
 CN Butanedioic acid, 2-[1-[[[carboxy-1H-indol-3-ylmethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:124835 CAPLUS
 DOCUMENT NUMBER: 122:8148
 TITLE: Biologically active compounds isolated from aerobic fermentation of *Trichoderma viride*
 INVENTOR(S): Harris, Guy H.; Milligan, James A.; Lingham, Russell B.; Zink, Deborah; Diez, Maria Teresa; Pelaez, Fernando; Jones, E. Tracy Turner; Mainz, Maria Sandrino; Bergstrom, James D.; et al.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418137	A1	19940818	WO 1994-US792	19940125
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5364948	A	19941115	US 1993-15498	19930209
AU 9462315	A	19940829	AU 1994-62315	19940125
PRIORITY APPLN. INFO.:			US 1993-15498	A 19930209
			US 1991-739758	B2 19910802
			US 1992-907730	B2 19920709
			WO 1994-US792	W 19940125

AB This invention relates to compds. of structural formula compound Q (I) isolated from an aerobic fermentation of *Trichoderma viride* MP5628, ATCC 74084


which are squalene synthase inhibitors and thus useful as cholesterol-lowering agents. These compds. are also potent antifungal agents. Addnl., they inhibit farnesyl protein transferase and function of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining compds.

of structural formula I.
 IT 158589-76-5P 158589-77-6P 158589-84-5P
 RL: BAC (Biological activity or effector, except adverse); BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
 (biol. active compds. isolated from aerobic fermentation of *Trichoderma viride*)


RN 158589-76-5 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(1H-indol-3-yl)ethyl]amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 160065-81-6 CAPLUS
 CN Butanedioic acid, 2-[1-[[[carboxy-1H-indol-3-ylmethyl]amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-77-6 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-84-5 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




IT 158589-79-8P 158589-80-1P 158589-81-2P
 158589-82-3P 158589-85-6P 158589-86-7P
 158589-13-4P 159530-24-2P
 RL: BAC (Biological activity or effector, except adverse); BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
 (biol. active compds. isolated from aerobic fermentation of *Trichoderma viride*)


L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 viride)
 RN 158589-79-8 CAPLUS
 CN Butanedioic acid, 2-[1-[[[1-carboxy-2-phenylethyl]amino]carbonyl]-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-80-1 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-phenylethyl]amino]carbonyl]-10-oxo-2-nonadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-81-2 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 158589-82-3 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)


L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 159530-24-2 CAPLUS
 CN Butanedioic acid, 2-[1-[[[1-carboxy-2-phenylethyl]amino]carbonyl]-2,9-heptadecadienyl]-2-hydroxy- (9CI) (CA INDEX NAME)




L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 158589-85-6 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-phenylethyl]amino]carbonyl]-10-oxo-2-hexadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-86-7 CAPLUS
 CN Butanedioic acid, 2-[1-[[[1-carboxy-2-phenylethyl]amino]carbonyl]-10-hydroxy-2-heptadecenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 158589-13-4 CAPLUS
 CN Butanedioic acid,
 2-[1-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-10-oxo-2,7-hexadecadienyl]-2-hydroxy- (9CI) (CA INDEX NAME)


CM 1

CRN 158589-82-3
 CMF C30 H43 N O10

L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1994:4128 CAPLUS
 DOCUMENT NUMBER: 120:4128
 TITLE: Isolation and structure elucidation of viridifungins A, B and C
 AUTHOR(S): Harris, Guy H.; Jones, E. Tracy Turner; Meinz, Maria S.; Nallin-Omstead, Mary; Helms, Gregory L.; Bills, Gerald F.; Zink, Deborah; Wilson, Kenneth E.
 CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Tetrahedron Letters (1993), 34(33), 5235-8
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The isolation and structure elucidation of 3 members of a novel family of amino acid-containing alkyl citrates, viridifungins A, B, and C, from Trichoderma viride are described. They are potent, broad spectrum antifungal agents and in vitro inhibitors of squalene synthase.
 IT 147023-34-5, Viridifungin A 147023-35-6, Viridifungin B 147023-36-7, Viridifungin C
 RL: BIOL (Biological study)
 (from Trichoderma viride)
 RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[1(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.




RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[1(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 147023-37-8P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and structure of)
 RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:183428 CAPLUS
 DOCUMENT NUMBER: 118:183428
 TITLE: Cholesterol-lowering agents, their manufacture with Trichoderma, and their use as fungicides or as biocides
 INVENTOR(S): Meinz, Maria Sandrino; Pelaez, Fernando; Omstead, Mary
 Nallin; Milligan, James A.; Diaz, Maria Teresa; Onishi, Janet C.; Bergstrom, James D.; Jenkins, Rosalind F.; Harris, Guy H.; et al.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 22 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 526936	A2	19930210	EP 1992-202300	19920725
EP 526936	A3	19930505		
R: CH, DE, FR, GB, IT, LI, NL				
CA 2074999	A1	19930203	CA 1992-2074999	19920730
JP 07173123	A	19950711	JP 1992-206802	19920803
PRIORITY APPL. INFO.:			US 1991-739758	A 19910802
			US 1991-739932	A 19910802
			US 1991-739950	A 19910802
			US 1992-907730	A 19920709

OTHER SOURCE(S): MARPAT 118:183428
 GI




AB Compds. I [R=benzyl, p-hydroxybenzyl, CH2-3-indoyl; 2,22,23=H, (substituted)C1-5-alkyl] and their use in medicaments for treatment of

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hypercholesterolemia, for inhibition of farnesyl-protein transferase, or for inhibiting fungal growth are claimed. I may be prepd. with Trichoderma viride ATCC 74084. Four I compds. were prepd. and tested for inhibition of squalene synthase (IC50 0.29-41.6 µg/mL) and farnesyl transferase (IC50 3.3-8 µM) as well as inhibition of fungal growth.
 IT 147023-34-5P 147023-35-6P 147023-36-7P

RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
 (manufacture of, with Trichoderma viride, for hypocholesteremic and antifungal)


RN 147023-34-5 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



RN 147023-35-6 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-phenylethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 147023-36-7 CAPLUS
 CN D-erythro-Pentonic acid, 3-C-carboxy-5-[[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-2,4,5-trideoxy-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 147023-37-8 CAPLUS
 CN D-erythro-Pentonic acid, 2,4,5-trideoxy-3-C-(methoxycarbonyl)-5-[[[(1S)-1-[(4-hydroxyphenyl)methyl]-2-methoxy-2-oxoethyl]amino]-5-oxo-4-[(1E)-9-oxo-1-hexadecenyl]]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
 Double bond geometry as shown.



IT 147023-38-9P 147023-39-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for hypocholesteremic and antifungal)
 RN 147023-38-9 CAPLUS
 CN Butanedioic acid, 2-hydroxy-2-[[1-[[[2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]]-, dimethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

G = $\text{CH}_2\text{-Ph}$

RN 147023-39-0 CAPLUS
 CH Butanediolic acid, 2-hydroxy-2-[1-[[[1-(1H-indol-3-ylmethyl)-2-methoxy-2-oxoethyl]amino]carbonyl]-10-oxo-2-heptadecenyl]-, dimethyl ester (9CI)
 (CA INDEX NAME)

